Guangyuyuan Selected for "2025 China Pharmaceutical Market Enterprise Ranking List (Traditional Chinese Medicine) TOP100"

(Source: Guangyuyuan (Rights Protection))

Recently, at the “MDS 2026 Fourth Medical and Pharmaceutical Marketing Big Data Summit,” the “Top 100 Chinese Pharmaceutical Companies in 2025” list was officially released. Guangyuyuan Chinese Medicine Co., Ltd. (hereinafter referred to as “Guangyuyuan”) was successfully selected for the “Top 100 Chinese Pharmaceutical Companies in 2025 (Traditional Chinese Medicine).”

The summit’s theme was “Building a New Ecosystem of Medical and Pharmaceutical Marketing Driven by Data.” It was an important part of the “2026 International Health Industry (Chongqing) Expo and the 11th Double Product Fair.” As one of the industry’s influential evaluation systems, the “Top 100 Chinese Pharmaceutical Companies in the Market” list is based on companies’ 2025 drug terminal sales data (retail and hospital channels), evaluated and approved by a panel of experts.

Currently, the pharmaceutical industry is undergoing profound changes, with data-driven approaches becoming key to innovation and growth. In the face of trends such as normalized centralized procurement, accelerated innovation, and channel integration, the transformation and upgrading of traditional pharmaceutical marketing models are increasingly urgent. This summit focused on industry frontiers, gathering data experts and leading enterprise decision-makers to explore new paradigms for growth in the digital era.

Guangyuyuan was founded in the 20th year of the Ming Jiajing era (1541 AD), with a history of over 485 years. It is one of China’s time-honored brands with a deep cultural heritage in traditional Chinese medicine. For a long time, the company has focused on core Chinese medicine business, adhering to the philosophy of “selecting authentic medicinal materials and following ancient processing methods.” It has continuously deepened its product development, with flagship products such as Gui Ling Ji, Ding Kun Dan, Angong Niuhuang Wan, and Niu Huang Qing Xin Wan. These products have gained long-term trust in medical and retail terminals due to their stable quality and efficacy.

In recent years, Guangyuyuan has continued to optimize its marketing system and upgrade its channel structure. In medical terminals, the company has strengthened evidence-based medicine construction, promoted clinical research and academic promotion of core products, and continuously improved recognition and accessibility in professional medical settings. In retail terminals, it has focused on building a diversified network covering key chain stores, regional leaders, and grassroots markets, enhancing terminal coverage quality through professional services.

Guangyuyuan’s inclusion in the Top 100 Traditional Chinese Medicine Companies list reflects an objective recognition of its performance in both medical and retail terminal markets over the past year. It also provides an important reference for future development. Facing the era of high-quality industry development, the company will continue to leverage its deep historical roots, deepen the construction of a comprehensive quality control system across the entire industry chain, and promote the integration of traditional techniques with modern technology. In the process of inheriting and innovating traditional Chinese medicine, Guangyuyuan strives to provide practical examples from time-honored brands for high-quality industry development, contributing more to the construction of a “Healthy China” and the revitalization of the Chinese medicine industry.

Video Channel

Massive information, precise analysis, all on Sina Finance APP